Related Experiment Videos
Invasive rhino-maxillary mucormycosis diagnosed before HSCT
Andrea Piccin1, John D Russell, Patrick Fleming
1Department of Haematology, Our Lady Hospital for Sick Children, Dublin, Ireland. andrea.piccin@ibts.ie
Pediatric Blood & Cancer
|July 29, 2006
Summary
Allogeneic hematopoietic stem cell transplantation (HSCT) was successful in a patient with invasive mucormycosis. This required extensive antifungal therapy and surgery before and after the transplant.
Area of Science:
- Hematology
- Mycology
- Transplant Surgery
Background:
- Invasive mucormycosis poses a significant risk for immunocompromised patients.
- Hematopoietic stem cell transplantation (HSCT) is a high-risk procedure for patients with active infections.
Observation:
- A patient with invasive mucormycosis involving the maxilla, nasal septum, and hard palate underwent allogeneic HSCT.
- The conditioning regimen was fully myeloablative.
Findings:
- Successful engraftment and long-term survival were achieved post-HSCT.
- Sustained antifungal therapy and aggressive surgical debridement were critical for managing the mucormycosis.
Implications:
- Allogeneic HSCT can be a viable option for select patients with invasive fungal infections.
- Multidisciplinary management involving infectious disease specialists, surgeons, and transplant teams is essential for favorable outcomes.
